4D Molecular Therapeutics, Inc. (FDMT) vs Lexicon Pharmaceuticals, Inc. (LXRX)
- 4D Molecular Therapeutics, Inc. FDMT 12.14 −5.67%
- Lexicon Pharmaceuticals, Inc. LXRX 1.52 −7.88%
4D Molecular Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. are both Biotechnology companies. 4D Molecular Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. are of similar size ($734.2M and $711.0M). 4D Molecular Therapeutics, Inc. grew revenue faster over the last twelve months: 278,712.1% against −29.0%. Lexicon Pharmaceuticals, Inc. has the higher net margin (−147.4% vs −194.7%) and the higher return on invested capital (−96.4% vs −186.9%). Across the 18 metrics below, Lexicon Pharmaceuticals, Inc. leads on 11 and 4D Molecular Therapeutics, Inc. on 7.
Valuation
Profitability
| Metric | FDMT | LXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 99.14% | 65.16% |
| Operating margin | (214.24%) | (131.43%) | 0.00% |
| Net margin | (194.74%) | (147.38%) | 0.00% |
| Free cash flow margin | (169.51%) | (156.71%) | 0.00% |
| Return on equity | (43.25%) | (40.21%) | (56.36%) |
| Return on assets | (37.09%) | (25.70%) | (48.04%) |
| Return on invested capital | (186.91%) | (96.36%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack